SAGE

Here's Why Sage Therapeutics Lost 53.3% in December

What happened

Shares of Sage Therapeutics (NASDAQ: SAGE) fell by more than half last month, according to data provided by S&P Global Market Intelligence. The nosedive occurred after the company announced that SAGE-217 failed a phase 3 study investigating the drug candidate's potential to treat major depressive disorder (MDD).

Investors had been keenly interested in the asset, which is taken orally and utilizes a novel mechanism of action compared to more commonly prescribed selective serotonin reuptake inhibitors (SSRIs). Analysts had expected the drug candidate to reach peak annual sales of $2 billion or more within a decade, but those hopes are now dashed.

The end-of-year dive meant that the pharma stock lost nearly 25% of its value in 2019.

A woman with a shocked expression looking at her phone.

Image source: Getty Images.

So what

Sage Therapeutics had an $8 billion valuation heading into the December data readout. Considering much of that was wrapped up in the success of SAGE-217, it's not too surprising that investors reacted so harshly to the failed clinical trial. In fact, the drug candidate barely outperformed placebo on the primary endpoint of achieving reductions on the Hamilton Rating Scale for Depression (HAM-D) total score at day 15.

The failure opened the door for Axsome Therapeutics (NASDAQ: AXSM) to take control of the next-generation depressive disorder market -- and the competitor took full advantage. Less than two weeks after SAGE-217 limped out of its phase 3 study, Axsome Therapeutics announced that a phase 3 clinical trial evaluating AXS-05 in MDD was successful.

Now what

Sage Therapeutics ended 2019 with a market cap of just $3.74 billion, compared to a market cap of $3.8 billion for Axsome Therapeutics. In other words, investors are clearly more optimistic about the future for the competitor than for Sage Therapeutics, which had garnered nearly all of the attention in the space for several years. Investors will have to await the next update from management to learn of the next steps for the pipeline.

10 stocks we like better than Sage Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Sage Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of December 1, 2019

 

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.